30484-77-6 Flunarizine dihydrochloride AKSci J10883
 
 
Loading Please Wait...
  J10883    AKSci Reference Standard
Flunarizine dihydrochloride, 99% (HPLC), powder
 
1-[Bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)piperazine dihydrochloride
IDENTITY
CAS Number:30484-77-6
MDL Number:MFCD00058198
MF:C26H28Cl2F2N2
MW:477.42
EINECS:250-216-6
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (HPLC), powder
Physical Form (at 20°C):Solid
Melting Point:214-217°C
Long-Term Storage:Store long-term at 2-8°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO: 5mg/mL; H2O: <1mg/mL; EtOH: 3mg/mL
Application(s):Calcium channel blocker

REVIEW
 Flunarizine is a non-selective calcium entry blocker with other actions including histamine H1 receptor blocking activity. It inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. It may help to reduce the severity and duration of attacks of paralysis associated with the more serious form of alternating hemiplegia. Flunarizine has been shown to significantly reduce headache frequency and severity in both adults and children. It has some side effects including weight gain, extrapyramidal effects, drowsiness and depression and is contraindicated in hypotension, heart failure and arrhythmia. Its use is avoided in patients with depression, severe constipation or those with extrapyramidal disorders.

REFERENCES
[1]Amery WK. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache. 1983 Mar;23(2):70-4.
[2] Wouters L, Amery W, Towse G. Flunarizine in the treatment of vertigo. J Laryngol Otol. 1983 Aug;97(8):697-704.
[3] Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984 Jan;27(1):6-44.
[4] Caers LI, De Beukelaar F, Amery WK. Flunarizine, a calcium-entry blocker, in childhood migraine, epilepsy, and alternating hemiplegia. Clin Neuropharmacol. 1987 Apr;10(2):162-8.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H302

Precautionary Statements
P264; P270; P301+P312; P330; P501

Current as of March 29, 2023

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.


CATEGORIES
 APIs and Bioactives > Calcium Channel Blockers


PubChem